Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To evaluate the toxicity and efficacy of a reduced dose intensity (mini-) FOLFOX-4 regimen as a first-line palliative chemotherapy in elderly patients (≥70 yr of age) with advanced colorectal cancer, data from prospective databases at Seoul National University Bundang Hospital and Seoul Municipal Boramae Hospital were analyzed. A total of 20 patients were enrolled between January 2001 and August 2004, and were treated with oxaliplatin 65 mg/m 2 on day 1, and with 2-hr infusions of leucovorin 150 mg/m 2 followed by a 5-FU bolus (300 mg/m2) and 22-hr continuous infusions (450 mg/m2) for 2 consecutive days every 2 weeks until progression, unacceptable toxicity or patient refusal. Sixteen patients were evaluable for response with an overall response rate of 43.8%. Median progression-free survival was 4.8 months (95% CI: 3.0-6.7) and overall survival was 13.5 months (95% CI: 11.1-16.0). The main side effects were anemia and neutropenia, which were observed in 20.8% and 17.7%, respectively, of the total cycles administered. There were no grade 4 toxicities and only one patient suffered from febrile neutropenia. No grade 3 toxicities occurred except for anemia (5.2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer.

Original languageEnglish
Pages (from-to)806-810
Number of pages5
JournalJournal of Korean Medical Science
Volume20
Issue number5
StatePublished - 1 Oct 2005

Fingerprint

Colorectal Neoplasms
Drug Therapy
oxaliplatin
Anemia
Municipal Hospitals
Febrile Neutropenia
Leucovorin
Neutropenia
Fluorouracil
Disease-Free Survival
Vomiting
Databases
Survival
Seoul

Keywords

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Folfox protocol

Cite this

@article{897aadb9fd5d42ec86e90d14b4f9f26d,
title = "Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer",
abstract = "To evaluate the toxicity and efficacy of a reduced dose intensity (mini-) FOLFOX-4 regimen as a first-line palliative chemotherapy in elderly patients (≥70 yr of age) with advanced colorectal cancer, data from prospective databases at Seoul National University Bundang Hospital and Seoul Municipal Boramae Hospital were analyzed. A total of 20 patients were enrolled between January 2001 and August 2004, and were treated with oxaliplatin 65 mg/m 2 on day 1, and with 2-hr infusions of leucovorin 150 mg/m 2 followed by a 5-FU bolus (300 mg/m2) and 22-hr continuous infusions (450 mg/m2) for 2 consecutive days every 2 weeks until progression, unacceptable toxicity or patient refusal. Sixteen patients were evaluable for response with an overall response rate of 43.8{\%}. Median progression-free survival was 4.8 months (95{\%} CI: 3.0-6.7) and overall survival was 13.5 months (95{\%} CI: 11.1-16.0). The main side effects were anemia and neutropenia, which were observed in 20.8{\%} and 17.7{\%}, respectively, of the total cycles administered. There were no grade 4 toxicities and only one patient suffered from febrile neutropenia. No grade 3 toxicities occurred except for anemia (5.2{\%}) and vomiting (1.0{\%}). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer.",
keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Folfox protocol",
author = "Kim, {Jee Hyun} and Do-Youn Oh and Yu, {Jung Kim} and Sae, {Won Han} and Choi, {In Sil} and Dong-Wan Kim and Seock-Ah Im and Taeyou Kim and Jong-Seok Lee and Heo, {Dae Seog} and Bang, {Yung Jue} and Noe, {Kyeong Kim}",
year = "2005",
month = "10",
day = "1",
language = "English",
volume = "20",
pages = "806--810",
journal = "Journal of Korean medical science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "5",

}

TY - JOUR

T1 - Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer

AU - Kim, Jee Hyun

AU - Oh, Do-Youn

AU - Yu, Jung Kim

AU - Sae, Won Han

AU - Choi, In Sil

AU - Kim, Dong-Wan

AU - Im, Seock-Ah

AU - Kim, Taeyou

AU - Lee, Jong-Seok

AU - Heo, Dae Seog

AU - Bang, Yung Jue

AU - Noe, Kyeong Kim

PY - 2005/10/1

Y1 - 2005/10/1

N2 - To evaluate the toxicity and efficacy of a reduced dose intensity (mini-) FOLFOX-4 regimen as a first-line palliative chemotherapy in elderly patients (≥70 yr of age) with advanced colorectal cancer, data from prospective databases at Seoul National University Bundang Hospital and Seoul Municipal Boramae Hospital were analyzed. A total of 20 patients were enrolled between January 2001 and August 2004, and were treated with oxaliplatin 65 mg/m 2 on day 1, and with 2-hr infusions of leucovorin 150 mg/m 2 followed by a 5-FU bolus (300 mg/m2) and 22-hr continuous infusions (450 mg/m2) for 2 consecutive days every 2 weeks until progression, unacceptable toxicity or patient refusal. Sixteen patients were evaluable for response with an overall response rate of 43.8%. Median progression-free survival was 4.8 months (95% CI: 3.0-6.7) and overall survival was 13.5 months (95% CI: 11.1-16.0). The main side effects were anemia and neutropenia, which were observed in 20.8% and 17.7%, respectively, of the total cycles administered. There were no grade 4 toxicities and only one patient suffered from febrile neutropenia. No grade 3 toxicities occurred except for anemia (5.2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer.

AB - To evaluate the toxicity and efficacy of a reduced dose intensity (mini-) FOLFOX-4 regimen as a first-line palliative chemotherapy in elderly patients (≥70 yr of age) with advanced colorectal cancer, data from prospective databases at Seoul National University Bundang Hospital and Seoul Municipal Boramae Hospital were analyzed. A total of 20 patients were enrolled between January 2001 and August 2004, and were treated with oxaliplatin 65 mg/m 2 on day 1, and with 2-hr infusions of leucovorin 150 mg/m 2 followed by a 5-FU bolus (300 mg/m2) and 22-hr continuous infusions (450 mg/m2) for 2 consecutive days every 2 weeks until progression, unacceptable toxicity or patient refusal. Sixteen patients were evaluable for response with an overall response rate of 43.8%. Median progression-free survival was 4.8 months (95% CI: 3.0-6.7) and overall survival was 13.5 months (95% CI: 11.1-16.0). The main side effects were anemia and neutropenia, which were observed in 20.8% and 17.7%, respectively, of the total cycles administered. There were no grade 4 toxicities and only one patient suffered from febrile neutropenia. No grade 3 toxicities occurred except for anemia (5.2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer.

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Colorectal Neoplasms

KW - Folfox protocol

UR - http://www.scopus.com/inward/record.url?scp=27744452928&partnerID=8YFLogxK

M3 - Article

C2 - 16224154

AN - SCOPUS:27744452928

VL - 20

SP - 806

EP - 810

JO - Journal of Korean medical science

JF - Journal of Korean medical science

SN - 1011-8934

IS - 5

ER -